$NKGen Biotech (NKGN.US)$ NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive scores, resulting in a clinical upgrade from moderate AD to mild AD after only three months on therapy. First patient...
NKGen Biotech股票討論區
NKGen生物科技宣布在第17屆阿茲海默症臨床試驗年會(CTAD)上舉辦海報發表
NKGen Biotech Inc.(納斯達克:NKGN)宣布將於2024年10月29日至11月1日在西班牙馬德里舉行的第17屆阿茲海默症臨床試驗年會(CTAD)上進行即將展示。 展示將涵蓋:
1. 一項第1期劑量逐步增加研究的最終報告和該隨訪中第1期群體的初步報告...
NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive scores, resulting in a clinical upgrade from moderate AD to mild AD after only three months on therapy.
First patient...
對於這項試驗來說,阿茲海默症患者的認知功能提高了90%,這是非常令人印象深刻的結果。
暫無評論